NCT04987086Recruiting
68Ga-PSMA PET in the Renal Cell Carcinoma
A Prospective, Multicenter Study of Diagnostic Efficiency of 68Ga-PSMA PET in the Patients With Locally Advanced and Advanced Renal Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 11 Jul 2021
- Start date
- 1 Jun 2021
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Xijing Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT04987086
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 1 Jun 2021 to the primary completion date, 1 Dec 2026
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;
Age
- Age ≤ 18 years old;
Other
- Can't stand lying flat in PET / CT examination;
- There are contraindications for 68Ga PSMA ligands;
- Renal function is impaired or hemodialysis is in progress.
Who the study is looking for
- 2017 AJCC renal cell carcinoma TNM stage III, IV lesions;
- In contrast-enhanced CT staging, suspicious metastases were found;
- There were no known peripheral or central venous problems;
- 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;
- Signed the informed consent form of voluntary participation in clinical trials.
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Hospital of Lanzhou University Coordinator of this site? Confirm its status | Lanzhou | China | Recruiting |
| Weinan Central Hospital Coordinator of this site? Confirm its status | Weinan | China | Recruiting |
| Shaanxi provincial people's hospital Coordinator of this site? Confirm its status | Xi'an | China | Recruiting |
| Xijing hospital Coordinator of this site? Confirm its status | Xi'an | China | Recruiting |
| Xijing 986 Hospital Coordinator of this site? Confirm its status | Xi'an | China | Recruiting |
| The Second Affiliated Hospital of Shaanxi University of Chinese Medicine Coordinator of this site? Confirm its status | Xianyang | China | Recruiting |
| Qinghai university affiliated hospital Coordinator of this site? Confirm its status | Xining | China | Recruiting |
| Affiliated Hospital of Yan'an University Coordinator of this site? Confirm its status | Yan’an | China | Recruiting |
| General Hospital of Ningxia Medical University Coordinator of this site? Confirm its status | Yinchuan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.